期刊文献+

右丙亚胺对表柔比星诱导乳腺癌细胞凋亡影响的研究 被引量:6

Influence of dexrazoxane on epirubicin cytotoxicity in human breast cancer cell lines
原文传递
导出
摘要 目的:探讨右丙亚胺(DEX)对表柔比星(EPI)诱导乳腺癌细胞凋亡的影响。方法:分别以不同浓度EPI作用于MCF-7、MDA-MB-231和BT474 3种乳腺癌细胞系24h,用MTT法检测抑制率,选择EPI最佳实验浓度;应用1.0μg/mL EPI与1.0、10和20μg/mL DEX分别及联合作用于3种乳腺癌细胞系,用MTT法检测抑制率,用流式细胞术检测细胞凋亡。结果:1.0μg/mL EPI组3种乳腺癌细胞的抑制率分别为(48.72±0.34)%、(64.40±2.63)%和(58.57±2.23)%,1.0μg/mL EPI联合1.0μg/mL DEX组3种细胞的抑制率分别为(46.44±1.35)%、(65.20±0.21)%和(57.52±2.31)%,1.0μg/mL EPI联合10μg/mL DEX组3种细胞抑制率分别为(47.57±2.20)%、(61.70±1.08)%和(59.54±1.26)%,1.0μg/mL EPI联合20μg/mL DEX组3种细胞抑制率分别为(43.85±1.19)%、(60.80±0.62)%和(58.25±3.50)%,EPI和DEX两药联合组(EPI∶DEX=1∶1和1∶10)与EPI组3种乳腺癌细胞系的抑制率比较差异无统计学意义,P>0.05;两者浓度为1∶20时对3种乳腺癌细胞系的增殖影响差异有统计学意义,P<0.05。流式细胞术检测1.0μg/mL EPI组3种乳腺癌细胞凋亡率分别为8.54%、11.25%和10.78%,EPI∶DEX=1∶10组3种乳腺癌细胞凋亡率分别为8.74%、11.85%和10.49%,两组细胞凋亡率差异无统计学意义,P>0.05。结论:心脏保护剂量的DEX并不影响EPI诱导的乳腺癌细胞凋亡效果。 OBJECTIVE: To investigate the influence of epirubicin(EPI) cytotoxicity by dexrazoxane(DEX) in hu- man breast cancer cell lines. METHODS: EPI of different concentrations was added into the culture fluid of human breast cancer cells. MTT method was used to detect the inhibition rate. Three breast cancer cell lines were treated with EPI (1.0 μg/mL),DEX(1.0,10 and 20 μg/mL),or with EPI: DEX (1 : 1,1 : 10,1 : 20). MTTmethod was used to detect the inhibition rate. Flow cytometry was used to detect the apoptosis of the cells. RESULTS: The inhibition rates of group A( 1.0μg/mL EPI) were (48.72± 0.34)~, (64.40±2.63)% and (58.57±2.23)% respectively. The inhibition rates of group E (1.0μg/mL EPI+1. 0 μg/mL DEX) were (46.44± 1.35) %0, (65.20±0.21) % and (57. 522±2.31) % respec tively. The inhibition rates of group F (1.0μg/mL EPI+10 μg/mL DEX) were (47.57±2.20) %, (61.70±1.08) % and (59.54±1.26) % respectively. The inhibition rates of group G (1.0 μg/mL EPI+ 20 μg/mL DEX) were (43.85 ± 1.19)%,(60.80±0.62)%and (58.25±3.50)% respectively. The apoptosis rates of group e(1.0 μg/mL EPI) were 8.54±11.25% and 10.78%,while the apoptosis rates of group d(1.0 μg/mL EPI+10 μg/mL DEX) were 8. 74%, 11.85% and 10.49%. Compared with the inhibition rate of 1.0 μg/mL EPI,the inhibition rates of 1.0 /zg/mL EPI corn bined with DEX(1.0,10 μg/mL) showed no statistical difference (P〉0.05). While the 1.0 μg/mL EPI combined with20μg/mlJ DEX had significant influence on the proliferation of breast cancer cells (P〈0.05). CONCLUSION: DEX given at cardioprotective doses does not alter the cytotoxicity efficacy of the EPI.
出处 《中华肿瘤防治杂志》 CAS 北大核心 2013年第12期914-917,共4页 Chinese Journal of Cancer Prevention and Treatment
关键词 乳腺肿瘤 表柔比星 右丙亚胺 心脏毒性 breast neoplasms epirubicin dexrazoxane heart inj uries
  • 相关文献

参考文献12

  • 1Marty M, Espie' M, Llombart A, et al. Mluticenter randomizedphase HI study of the cardioprotective effect of dexrazoxane (car-dioxane-) in advanced/metastatic breast cancer patients treatedwith anthracycline-based chemotherapy [J]. Ann Oncol, 2006 .17(4):614-622. 被引量:1
  • 2马军,沈志祥,秦叔逵.防治蒽环类抗肿瘤药物心脏毒性的中国专家共识(2011版)[J].临床肿瘤学杂志,2011,16(12):1122-1129. 被引量:42
  • 3Testore F,Milanese S,Ceste M,et al. Cardioprotective effect ofdexrazoxane in patients with breast cancer treated with anthracy-clines in adjuvant setting: a 10-year single institution experience[J]. Am J Cardiovasc Drugs, 2008 ,8(4) : 257-263. 被引量:1
  • 4Hensley ML, Hagerty KL, Kewalramani T, et al. American Soci-ety of Clinical Oncology 2008 clinical practice guideline update:use of chemotherapy and radiation therapy protectants[J]. J ClinOncol,2009,27C1):127-145. 被引量:1
  • 5Dal Ben D,Palumbo M,Zagotto G,et al. DNA topoisomerase IIstructures and anthracycline activity: insights into ternary com-plex formation[J]. Curr Pharm Des,2007 ,13(27) : 2766-2780. 被引量:1
  • 6Sawyer DB’Peng X,Chen B,et al. Mechanisms of anthracyclinecardiac injury: can we identify strategies for cardioprotection?[J]. Prog Cardiovasc Dis,2010,53(2) : 105-113. 被引量:1
  • 7Doroshow JH. Dexrazoxane for the prevention of cardiac toxicityand treatment of extravasation injury from the anthracycline an-tibiotics[J]. Curr Pharm Biotechnol,2012,13(10) : 1949-1956. 被引量:1
  • 8Hasinoff BB,Herman EH. Dexrazoxane : how it works in cardiacand tumor cells. Is it a prodrug or is it a drug? [J]. CardiovascToxicol,2007,7(2) :140-144. 被引量:1
  • 9Roti Roti EC,Salih SM. Dexrazoxane ameliorates doxorubicin-in-duced injury in mouse ovarian cells [J]. Biol Reprod,2012,86(3):96. 被引量:1
  • 10Van Dalen EC,Caron HN?Dickinson HO,et al. Cardioprotectiveinterventions for cancer patients receiving anthracyclines[J]. Co-chrane Database Syst Rev,2011,15(6) :CD003917. 被引量:1

二级参考文献54

共引文献76

同被引文献59

  • 1周蕾,赖永洪.槲皮素对柔红霉素致大鼠心肌细胞损伤的保护作用[J].实用儿科临床杂志,2006,21(13):855-856. 被引量:6
  • 2Swain SM. Adult multi-center trials using dexrasoxane to protect against cardiac toxicity[J]. Semin Onco1,1998,25(4 Suppl 10):S43-7. 被引量:1
  • 3Blowers E,Hall K. Managing adverse events in the use of beva- cizumab and chermotherapy[J]. Nurs,2009,180:351-6. 被引量:1
  • 4Jones A,Barlow M,Barrett-Lee PJ. Management of cardiac health in trastuznm treated patients with breast cancer .updated United Kingdom National Cancer Research Institute recommendation for monitoring[J]. Sr J Cancer,2009,100(5):684-92. 被引量:1
  • 5Lipshuhz SE,Scully RE,Lipsitz SR,et al. Assessment of dexrazoxaneas a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastie leukacmla:long-term follow-up of a prospective, randomised,muhicentre tria 1 [J]. Lancet Oncol,2010,11 (10):950-61. 被引量:1
  • 6Kaiserova H,Simunek T,van der Vijgh WJ,et al. Flavonoids as protectors against doxoruhicin cardiotoxicity:role of iron chelation. antioxidant activity and inhibition of ca bonyl reduetase[J]. Biochim Biophys Aeta,2007,1772(9): 1065-74. 被引量:1
  • 7FitzPatrick WM,Dervisis NG,Kitchell BE. Safety of concurrent administration of dexrazoxane and doxorubiein in the canine cancer patient[J]. Vet Cutup Oncol,2010,8(4):273-82. 被引量:1
  • 8Junjing Z,Yah Z,Baulu Z. Scavenging-effeets of dexrazoxane on free radicals[J]. J Clin Bioehem Nutr,2010,47(3):238-45. 被引量:1
  • 9Jurcut R,Wildiem H,Ganame J,et al. Detection and monitoring of cardiotoxicity-whal does modern cardiology offer?[J]. Support Care Cancer,2008,16(5):437-45. 被引量:1
  • 10Hensley ML,Hagerty KL,Kewalramani T,et al. American Society of Clinical Oncology 2008 clinical practice guideline update: use ofchemotherapy and radiation therapy protectants[J]. J Clin Oncol,2009,27( 1):127 -45. 被引量:1

引证文献6

二级引证文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部